Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Urinary Bladder Overactive Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence

NCT01157377
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
AGN-214868, AGN-214868 placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Jul 22, 2026, 9:48 PM EDT
Completed No phase listed Observational

A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)

NCT02386072
View directory record Official record
Conditions
Urinary Bladder Overactive, Overactive Bladder, Urinary Bladder Diseases, Urologic Diseases
Interventions
mirabegron, antimuscarinic medication
Drug
Lead sponsor
Astellas Scientific & Medical Affairs, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
75
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Jul 22, 2026, 9:48 PM EDT
Completed Not applicable Interventional

FemPulse Therapy First-in-Human Experience

NCT03874637
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Treament, Sham Control
Device
Lead sponsor
FemPulse Corporation
Industry
Eligibility
21 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Woodbury, Minnesota • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Jul 22, 2026, 9:48 PM EDT
Terminated No phase listed Observational

A Pilot Trial in a Sleep Laboratory Setting to Observe Night Time Bladder Function of Subjects With Overactive Bladder (OAB)

NCT01099345
View directory record Official record
Conditions
Bladder Function
Interventions
cystometry (CMG), polysomnography (PSG)
Procedure
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Jul 22, 2026, 9:48 PM EDT
Completed Phase 3 Interventional

Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder

NCT00454740
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
solifenacin succinate
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
104
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Jul 22, 2026, 9:48 PM EDT
Active, not recruiting Not applicable Interventional

INTIBIA Pivotal Study

NCT05250908
View directory record Official record
Conditions
Urinary Incontinence, Urge, Urinary Bladder, Overactive, Urinary Bladder Diseases, Urologic Diseases, Lower Urinary Tract Symptoms, Urological Manifestations
Interventions
INTIBIA Therapeutic, INTIBIA Non-Therapeutic
Device
Lead sponsor
Coloplast A/S
Industry
Eligibility
22 Years to 80 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Beverly Hills, California • Los Angeles, California • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jul 22, 2026, 9:48 PM EDT
Completed Phase 3 Interventional Results available

A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis

NCT00876447
View directory record Official record
Conditions
Overactive Bladder
Interventions
Botulinum Toxin Type A 300U, Botulinum Toxin Type A 200U
Biological
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Middlebury, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Jul 22, 2026, 9:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Symptoms of Lower Urinary Tract Dysfunction Phenotyping Study

NCT02485808
View directory record Official record
Conditions
Lower Urinary Tract Symptoms
Interventions
None-observational, Magnetic Resonance Imaging (MRI), Multimodal Automated Sensory Testing System, Auditory Sensitivity Test
Other · Procedure
Lead sponsor
Arbor Research Collaborative for Health
Other
Eligibility
18 Years and older
Enrollment
1,879 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
6
States / cities
Chicago, Illinois • Iowa City, Iowa • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Jul 22, 2026, 9:48 PM EDT
Terminated Phase 3 Interventional Results available

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1

NCT02660138
View directory record Official record
Conditions
Urinary Incontinence, Overactive Bladder
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
32
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Jul 22, 2026, 9:48 PM EDT
Completed Phase 4 Interventional Results available

Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.

NCT01093534
View directory record Official record
Conditions
Detrusor Overactivity, Overactive Bladder
Interventions
Placebo, solifenacin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
New York, New York • West Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Jul 22, 2026, 9:48 PM EDT
Terminated Phase 4 Interventional

Use of Percutaneous Tibial Nerve Stimulation With Solifenacin or Placebo to Treat Refractory Overactive Bladder

NCT01764893
View directory record Official record
Conditions
Overactive Bladder
Interventions
PTNS plus solifenacin, Placebo
Other
Lead sponsor
Bay State Clinical Trials, Inc.
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Jul 22, 2026, 9:48 PM EDT
Completed Phase 2 Interventional

Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder

NCT01868516
View directory record Official record
Conditions
Overactive Bladder
Interventions
dexmecamylamine, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
125
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 109 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Jul 22, 2026, 9:48 PM EDT
Recruiting Phase 3 Interventional

Oxybutynin for Post-surgical Bladder Pain and Urgency

NCT03952299
View directory record Official record
Conditions
Overactive Bladder Syndrome, Neuropathic Bladder
Interventions
Oxybutynin Transdermal Patch, Oral Oxybutynin
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
4 Years to 8 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 22, 2026, 9:48 PM EDT
Completed Phase 3 Interventional Results available

A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo

NCT00350636
View directory record Official record
Conditions
Overactive Bladder
Interventions
Oxybutynin topical gel, Placebo topical gel
Drug · Other
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
63
States / cities
Birmingham, Alabama • Homewood, Alabama • Mobile, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated May 9, 2010 · Synced Jul 22, 2026, 9:48 PM EDT
Terminated Phase 2 Interventional

Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients

NCT00332319
View directory record Official record
Conditions
Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder
Interventions
GW679769
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Long Beach, California • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Jul 22, 2026, 9:48 PM EDT
Enrolling by invitation Not applicable Interventional

Transvaginal Detrusor Nerve Radiofrequency Ablation for Treatment of Overactive Bladder

NCT06283498
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
Device Morpheus8V
Device
Lead sponsor
InMode MD Ltd.
Industry
Eligibility
21 Years to 80 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Corona del Mar, California • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Jul 22, 2026, 9:48 PM EDT
Recruiting Phase 4 Interventional

Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A

NCT04305743
View directory record Official record
Conditions
Urinary Bladder, Overactive, Incontinence, Urge, Incontinence, Urinary, Urinary Urge Incontinence, Urinary Frequency More Than Once at Night, Nocturia
Interventions
OnabotulinumtoxinA 100 UNT
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Jul 22, 2026, 9:48 PM EDT
Completed No phase listed Observational

The Urinary Microbiome in Patients Receiving Intradetrusor Botox Injections

NCT04479709
View directory record Official record
Conditions
Overactive Bladder
Interventions
Not listed
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
60 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Jul 22, 2026, 9:48 PM EDT
Completed Phase 3 Interventional Results available

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00912964
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
2,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
82
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Jul 22, 2026, 9:48 PM EDT
Terminated Not applicable Interventional Results available

TENS Used for Pain Management During Office Cystoscopy Botox Injections

NCT04448171
View directory record Official record
Conditions
Overactive Bladder
Interventions
Active TENS, Sham TENS
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Jul 22, 2026, 9:48 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Practice-Based Intervention To Improve Care for a Diverse Population Of Women With Urinary Incontinence

NCT05534412
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Academic Detailing, Electronic Clinical Decision Support, APP Co-management, Electronic Referral
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
4
States / cities
La Jolla, California • Los Angeles, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 22, 2026, 9:48 PM EDT
Recruiting Not applicable Interventional

Fluoroscopy Radiation Reduction During Sacral Neuromodulation Lead Placement

NCT04527445
View directory record Official record
Conditions
Radiation Exposure, Overactive Bladder, Urge Incontinence, Urgency-frequency Syndrome
Interventions
Reduced radiation fluoroscopy, Conventional fluoroscopy
Procedure
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 89 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 22, 2026, 9:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Percutaneous Tibial Nerve Stimulation Maintenance: Monthly Therapy or Per Patient Requested Need

NCT03136601
View directory record Official record
Conditions
Overactive Bladder
Interventions
PTNS maintenance
Other
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jul 22, 2026, 9:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)

NCT00862745
View directory record Official record
Conditions
Urge Urinary Incontinence, Overactive Bladder
Interventions
Fesoterodine, Matching Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
645 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
13
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Jul 22, 2026, 9:48 PM EDT